Oxis deal

OXIS (Portland, Ore.) completed the previously announced acquisition of Therox Pharmaceuticals Inc., a Philadelphia developer of antioxidant compounds and free radical scavengers (see BioCentury June 19). OXIS, which closed at $2.953 on Friday, issued 1.44 million shares to the privately held company, which can achieve an additional $2 million upon the commercialization of certain Therox products. ...